CD19: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
(12 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
:<span style="color:navy">'''Summary'''</span> | :<span style="color:navy">'''Summary'''</span> | ||
:CD19 expressed through most stages of B-cell development and is considered a pan | :CD19 expressed through most stages of B-cell development and is considered a pan B-cell marker i.e. present at early B-cell commitment until plasma cell stage | ||
Line 20: | Line 20: | ||
<span style="color:navy">'''Diagnostic role'''</span> | <span style="color:navy">'''Diagnostic role'''</span> | ||
* | *CD19 is very useful in the confirmation of B-lineage of normal and malignant b cells although not etirely specific | ||
*Note however that expression may be absent in very early cases of all and that CD19 and is absent on plasma cells and in some cases of DLBCL | |||
*The level of expression may be helpful with high levels in hairy cell leukaemia with relatively low levels of expression in CLL | |||
*CD19 is a fairly common aberrant marker in AML particularly cases with the t 8;21 cytogenetic lesion | |||
Line 42: | Line 39: | ||
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;" | {| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;" | ||
|- | |- | ||
!colspan="8"| | !colspan="8"|'''Expression in primitive cell types'''</font> | ||
|- | |- <span style="font-size:70%"> | ||
! AML !! CMML !! B ALL !! | !AML!!CMML !!B ALL !!BL ||T ALL !!ETP ALL !!MPAL ||Hgn</span> | ||
|- | |-<span style="font-size:70%"> | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #66e0ff; color:black"|5-20%* | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #E6FAFF; color:wblack"|<5% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100%** | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #E6FAFF; color:wblack"|<5% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #E6FAFF; color:wblack"|<5% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #00b8e6; color:white"|40-80% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100% | ||
|- | |- | ||
|} | |} | ||
<span style="font-size:90%">'''Notes:''' | <span style="font-size:90%">'''Notes:''' ''**''While a good marker of B lineage it may not be expressed in more primitive phenotype ALL, there is also a recognised abberrant expression in AML (particularly cases with t)8;21) </span> | ||
Line 63: | Line 60: | ||
|- | |- | ||
!colspan="8"|'''Expression in mature B cell neoplasms''' | !colspan="8"|'''Expression in mature B cell neoplasms''' | ||
|- | |- <span style="font-size:70%"> | ||
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL | ! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL | ||
|- | |-<span style="font-size:70%"> | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100%* | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #00b8e6; color:white"|80-100% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100%** | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100%** | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #00b8e6; color:white"|40-80% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #004466; color:white"|80-100% | ||
|style="width: 12.5%; background: | |style="width: 12.5%; background: #66e0ff; color:black"|5-20%* | ||
|- | |- | ||
|} | |} | ||
<span style="font-size:90%">'''Notes:''' | <span style="font-size:90%">'''Notes:''' Level of expression is important with low expression in CLL* and typically high expression in HCL </span> | ||
Line 87: | Line 84: | ||
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL | ! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL | ||
|- | |- | ||
|style="width: 14.25%; background: | |style="width: 14.25%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 14.25%; background: | |style="width: 14.25%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 14.25%; background: | |style="width: 14.25%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 14.25%; background: | |style="width: 14.25%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 14.25%; background: | |style="width: 14.25%; background: #E6FAFF; color:black"|<5% | ||
|- | |- | ||
|} | |} | ||
---- | ---- |
Latest revision as of 21:38, 4 July 2023
- Summary
- CD19 expressed through most stages of B-cell development and is considered a pan B-cell marker i.e. present at early B-cell commitment until plasma cell stage
Normal expression and function
CD19 forms part of the normal B-cell receptor, and plays a major role in the recruiting and activating signalling proteins involved in B-cell activation. it reliably expressed by most normal B lymphocytes and also by follicular dendritic cells. Expression is acquired very early during normal B-cell development and tends to increase as B cells mature before becoming lost during the transition to plasma cells.
Diagnostic role
- CD19 is very useful in the confirmation of B-lineage of normal and malignant b cells although not etirely specific
- Note however that expression may be absent in very early cases of all and that CD19 and is absent on plasma cells and in some cases of DLBCL
- The level of expression may be helpful with high levels in hairy cell leukaemia with relatively low levels of expression in CLL
- CD19 is a fairly common aberrant marker in AML particularly cases with the t 8;21 cytogenetic lesion
SUMMARY TABLES
Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name
Expression in primitive cell types | |||||||
---|---|---|---|---|---|---|---|
AML | CMML | B ALL | BL | T ALL | ETP ALL | MPAL | Hgn |
5-20%* | <5% | 80-100%** | 80-100% | <5% | <5% | 40-80% | 80-100% |
Notes: **While a good marker of B lineage it may not be expressed in more primitive phenotype ALL, there is also a recognised abberrant expression in AML (particularly cases with t)8;21)
Expression in mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
80-100%* | 80-100% | 80-100% | 80-100%** | 80-100%** | 40-80% | 80-100% | 5-20%* |
Notes: Level of expression is important with low expression in CLL* and typically high expression in HCL
Expression in mature T cell neoplasms* | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL/Sezary | T-PLL | T-LGL | NK-LGL | ||
<5% | <5% | <5% | <5% | <5% |